In conclusion, we focused on advanced TYK2 inhibitor to develop a new ROS-responsive topical formula of deucravacitinib based on PEPS micelles with inherent antioxidative capacity for psoriasis treatment. The gene discussed is TYK2; the disease is psoriasis.